After missing analysts' second-quarter sales and earning expectations, Walgreens Boots Alliance vowed to cut more than $1.5 billion in costs by fiscal year 2022, according to CNBC.

A federal  judge in New York has ruled that Novartis must face trial in a case accusing the drugmaker of paying millions of dollars in kickbacks to physicians to boost prescription rates, according to Reuters.

An Oklahoma pharmacy owner has been charged with orchestrating a scheme that defrauded Medicare and Medicaid out of more than $1 million.

Martin Shkreli was placed in solitary confinement after a report surfaced that the infamous "pharma bro" was using a contraband cellphone to run his pharmaceutical company from prison, according to Forbes.

The U.S. Health Resources & Services Administration launched a long-awaited website for safety-net providers participating in the 340B Drug Pricing Program April 1.

Novartis has agreed to acquire a subsidiary of IFM Therapeutics for a potential total of nearly $1.6 billion, including $310 million up front, and up to $1.27 billion in milestone payments, according to Reuters.

After facing pressure from federal regulators, Walgreens Boots Alliance is piloting several tobacco-free stores in the U.S., but doesn't plan to halt sales entirely, according to The Wall Street Journal.

Mylan must face a class-action lawsuit over its lifesaving allergy treatment EpiPen, a judge ruled last week, according to Bloomberg.

Court documents filed by Ohio Attorney General Dave Yost reveal that the state is planning more legal action against pharmacy benefit managers, according to The Columbus Dispatch.

If Purdue Pharma files for bankruptcy to protect itself from thousands of lawsuits claiming the OxyContin maker contributed to the nationwide opioid epidemic, some of its newly created subsidiaries will likely come under scrutiny, according to a STAT news report.